RxDoctor Payments Data

Vaqar Ali, MD

Interventional Cardiology · Jacksonville, FLNPI 1154379048

Payments from drug & device makers

$235,266in general payments, 2019–2025

Across 628 payments — averaging $374.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$71K
  • Endologix LLC$54K
  • M.a. Med Alliance S.A.$47K
  • Intact Vascular, Inc.$14K
  • Medalliance LLC$13K
  • Bard Peripheral Vascular, Inc.$13K
  • plus $24K from 54 others

What the payments were for

  • Consulting fees$6,55022%
  • Speaking & faculty fees$1,6505%
  • Travel & lodging$2,5198%
  • Food & beverage$19,45864%
  • Education$480%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott89$70,703
Endologix LLC49$53,642
M.a. Med Alliance S.A.11$46,582
Intact Vascular, Inc.5$13,906
Medalliance LLC3$13,400
Bard Peripheral Vascular, Inc.42$13,046
Angiodynamics, Inc.3$6,687
Cardiovascular Systems Inc.20$3,430
Edwards Lifesciences29$1,507
Abiomed15$1,459
Medtronic(2 entities)43$1,359
Boston Scientific20$1,236
Amgen38$783
Celonova Biosciences, Inc.3$619
Imperative Care, Inc17$543
Novartis20$492
Merck22$453
AstraZeneca21$412
Siemens Medical Solutions USA, Inc.8$409
Cvrx, Inc.13$349
Shockwave Medical, Inc8$349
Philips North America LLC8$346
Opsens Inc.4$341
E.r. Squibb & Sons, L.L.C.22$335
Boehringer Ingelheim14$282
Avantec Vascular Corporation3$281
Pfizer9$251
Bayer14$233
Penumbra, Inc.9$225
Actelion Pharmaceuticals US, Inc.7$194
Inspire Medical Systems, Inc.2$176
Johnson & Johnson11$164
Cook Medical LLC7$132
W. L. Gore & Associates, Inc.1$111
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)3$73
Innovation Technologies Inc1$59
Kiniksa Pharmaceuticals International, PLC3$55
Sanofi-aventis U.S. LLC2$55
Amarin Pharma, Inc.3$55
Jubilant Draximage, Inc.1$49
Asahi Intecc USA, Inc.2$45
Lexicon Pharmaceuticals, Inc.2$36
Tactile Systems Technology Inc2$33
United Therapeutics Corporation1$32
Alnylam Pharmaceuticals Inc.1$31
Baxter Healthcare2$30
Kerecis Limited1$29
Kestra Medical Technology Services, Inc.1$27
Cordis US CORP.1$24
Novo Nordisk1$24
Bristol Myers Squibb1$23
Veryan Medical Incorporated1$23
Gilead1$19
Medicomp Inc1$18
Acutus Medical, Inc.1$17
Irhythm Technologies, Inc.1$15
Cashflow Solutions, LLC1$13
GSK1$12
AbbVie1$12
Chiesi USA, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$235,266 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$709,493
Medicare patients
1,391
Services billed
7,984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban184$228,306
CamzyosMavacamten13$93,337
XareltoRivaroxaban70$92,384
JardianceEmpagliflozin79$90,578
EntrestoSacubitril/Valsartan65$86,647
FarxigaDapagliflozin Propanediol31$42,562
Repatha SureclickEvolocumab50$41,972
Repatha SyringeEvolocumab26$23,420
OzempicSemaglutide12$11,622
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,532
Ranolazine ErRanolazine41$6,844
Prasugrel Hcl34$6,187
ClopidogrelClopidogrel Bisulfate381$3,478
Metoprolol Succinate270$3,066
Atorvastatin Calcium372$2,976

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$251$228,306184 claims
E.r. Squibb & Sons, L.L.C.Camzyos$335$93,33713 claims
Johnson & JohnsonXarelto$164$92,38470 claims
Boehringer IngelheimJardiance$282$90,57879 claims
NovartisEntresto$492$86,64765 claims
AstraZenecaFarxiga$412$42,56231 claims
Novo NordiskOzempic$24$11,62212 claims
GSKTrelegy Ellipta$12$10,53211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →